Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist

2021-04-21

Page View：

On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA). HG381 for injection is a new Category I Chemical Drug and is clinically intended to be used for the treatment of advanced tumors.

HG381 is new molecular entity developed by HitGen based on the DNA-encoded compound Library (DEL) technology and small molecule new drug research and development platform. HG381 is the first STING agonist approved for clinical trials in China and the 4^th second-generation STING agonist for clinical trial in the world. In addition, HG381 is the 3^rd new drug project approved for clinical trial by HitGen.

As a leading R&D partner of HitGen, Shanghai Medicilon Inc. (Medicilon) provided preparation R&D services for HG381. In order to ensure the quality of R&D, Medicilon helped to accelerate the R&D process through rigorous trial design, meticulous project management and efficient communication.

❖ Medicilon’s preparation services

Medicilon's preparation laboratory and workshop area is about 4,000 square meters, with 100 professional R&D teams, of which more than 40% are masters/doctors, and more than 95% are undergraduates. The team has rich experience in successful research and development of innovative drugs, consistency evaluation, and improved new drugs, and experience in China-US dual filing and project management. The Medicilon pharmaceutical preparation R&D team has successfully cooperated with well-known large and medium-sized pharmaceutical companies worldwide, and has accumulated 18 years of experience in the research and application of innovative drugs and generic drugs. We provide one-stop and systematic preparation R&D services covering innovative drugs and generic drugs to meet the needs of customers at different stages of R&D.

Medicilon congratulated HitGen on its rapid clinical trail approval and wishes the HG381 will open a new stage for the treatment of advanced tumor. Medicilon also wishes that the DEL screening technology would enable more innovative drug discovery to benefit more patients. At the same time, Medicilon will continue to uphold the principle of “Innovation Driven, Quality First”, to accelerate the development of preclinical new drugs.

About HitGen

HitGen is a biotech company focused on lead generation and optimization of innovative drug discovery research process. HitGen has its headquarters based in Chengdu, China. Its core technology is centered around the synthesis and screening of a rapidly expanding and proprietary DNA-encoded compound libraries of novel small and macrocyclic molecules for lead generation. HitGen has also established key scientific research capabilities of medicinal chemistry, bioscience and computational science with > 200 research staffs. It currently has over 20 preclinical projects on going in oncology, CVD, inflammation/ respiratory, metabolism and ophthalmology. Collaborations with a number of international and domestic pharmaceutical and biotechnology companies have been established.

About Medicilon

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. Medicilon grows together with the clients and delivers the new drug research and development services to more than 700 clients globally. Medicilon is proud to contribute to human health in the globe.